Comprehensive Review of CRISPR Gene Therapy: Potential Applications and Challenges for Sickle Cell Disease and Beta-Thalassemia

August 30, 2026

International Journal of Basic & Clinical Pharmacology Global

Overview

A comprehensive review covered the discovery, mechanism, therapeutic applications, and current limitations of CRISPR-Cas9, a revolutionary genome editing technology that precisely modifies DNA sequences using RNA-guided nucleases. It highlights CRISPR’s vast potential for treating numerous genetic disorders, including inherited blood diseases like sickle cell disease and beta-thalassemia, hereditary retinal diseases, and muscular dystrophies. While challenges such as off-target effects, PAM sequence constraints, DNA damage-induced toxicity, and immune responses persist, advancements in delivery methods and high-fidelity Cas9 variants are addressing these limitations.

In Depth

Key Findings

A comprehensive review has been published detailing the groundbreaking CRISPR-Cas9 system, a revolutionary genome editing technology that precisely modifies DNA sequences using RNA-guided nucleases. This review covers its discovery, mechanism of action, diverse therapeutic applications, and current limitations. It underscores the immense potential of CRISPR gene therapy for a wide range of genetic disorders, from severe inherited blood diseases like sickle cell disease and beta-thalassemia to hereditary retinal diseases and muscular dystrophies.

Technical/Clinical Details

The CRISPR-Cas9 system functions by a guide RNA recognizing a specific DNA sequence, prompting the Cas9 nuclease to create a double-strand DNA break (DSB) at that site. Cellular DNA repair mechanisms (non-homologous end joining or homology-directed repair) then facilitate target gene knockout, gene insertion, or precise point mutation correction. In clinical applications, approaches for sickle cell disease (SCD) and beta-thalassemia are highly promising, involving ex vivo editing of patient’s hematopoietic stem cells to correct mutated hemoglobin genes or induce fetal hemoglobin expression. For instance, in SCD, editing specific sites in the Bcl11a gene aims to reactivate gamma-globin expression to prevent sickling. For hereditary retinal diseases, in vivo gene editing is being explored to directly correct gene mutations causing photoreceptor degeneration. In muscular dystrophies, particularly Duchenne muscular dystrophy (DMD), efforts are underway to delay disease progression by exon skipping or inserting functional dystrophin gene fragments.

However, CRISPR gene therapy faces several challenges. Off-target effects, where unintended genomic sites are edited, pose risks of genotoxicity and unwanted mutations. PAM sequence constraints limit the sites Cas9 can cleave, restricting editing flexibility. DNA damage-induced toxicity refers to the stress DSBs themselves impose on cells, potentially activating pathways like P53, leading to cell death or selective pressure. Furthermore, immune responses against the delivered Cas9 protein can diminish therapeutic efficacy. These challenges are being addressed through the development of high-fidelity Cas9 variants (e.g., SpCas9-HF1), optimization of Cas9 delivery methods (e.g., improved lipid nanoparticles, adeno-associated viral vectors), and the introduction of next-generation editing technologies like base editing and prime editing, which avoid DSBs.

Background & Context

The discovery of CRISPR-Cas9, which led to the Nobel Prize in Chemistry in 2020, marked a watershed moment in the history of gene therapy. While traditional gene therapy primarily focused on gene replacement, CRISPR’s ability to directly ‘correct’ disease-causing genes opened possibilities for more fundamental treatments. The global gene therapy market is rapidly expanding, driven by increasing expectations for curative treatments for genetic diseases. Regulatory bodies are also establishing evaluation criteria for safety and efficacy, leading to a growing number of approved clinical trials.

Strategic Significance & Outlook

CRISPR gene therapy is expected to broaden its applications to more diseases in the coming years, driven by improvements in delivery technologies, diversification and optimization of Cas proteins, and the emergence of new editing strategies to minimize off-target effects. Alongside the advancement of personalized medicine, CRISPR is poised to become a leading platform technology offering groundbreaking therapeutic options for many genetic diseases previously considered untreatable.

Source: https://www.ijbcp.com/index.php/ijbcp/article/view/6382

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.